Total Funding
44
56
Total FundingSeries B raised
Growth Score
-7 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
21435
Lykos Therapeutics catalyzes healing and well-being through psychedelic drug development, therapist training programs.
- Amy Emerson: CEO
- Berra Yazar-Klosinski: Chief Science Officer
About the Company
Lykos Therapeutics' goal is to revolutionize the way mental health is addressed. By creating innovative medicines and therapeutic techniques to treat mental health disorders, we hope to upend the status quo. With over thirty years of expertise investigating therapies aided by psychedelics, we continue to be committed to adhering to rigorous
science so that we can create and market innovative treatment alternatives.
Women Led
